Pharmos — Shareholder Meeting (October 2006)
26 slides from Pharmos's shareholder meeting presentation, Oct 26, 2006

Slide 1: Annual Shareholders Meeting October 2006
Annual Shareholders Meeting October 2006 PHARMOS

Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company's pipeline products, to the potential from t

Slide 3: Last Year
Last Year Objective: Broaden product pipeline by acquiring company or products with reliable clinical data in specific areas of interest Advance internal CB2 platform & Nano delivery project. Strengthen management

Slide 4: The Vela Acquisition Summary
The Vela Acquisition Summary Fulfills strategic objective / excellent fit Expands pipeline – later stage clinical drugs Complements focus on pain /inflammation Dextofisopam – successful Phase 2a in IBS Two additional later-stage assets Tianeptine – strong follow-on for IBS VPI-013 – Phase 2 asset fo

Slide 5: The New Pharmos Pipeline
The New Pharmos Pipeline * Nano-Tech emulsion delivery Preclinical Phase 1 Phase 2 Phase 3 Dextofisopam (Vela) IBS Tianeptine (Vela) PRS-XXX/ CB2 Agonist Autoimmune Neuropathic Pain Topical NSAID’s * Nano Diclofenac for OA Nano Ketorolac for OA Cannabinor (CB2) IV Nociceptive Pain Neuropathic Pain I

Slide 6: IBS Overview
IBS Overview PHARMOS

Slide 7: IBS – A Significant Underserved Market
IBS – A significant Underserved Market Estimated >10% prevalence in US* (~1/3 significant) Women to men 3 to 1 Responsible for 3.7 million annual visits to GI specialists* Patients unsatisfied with current treatment * in 2004 * Saito et al. The epidemiology of irritable bowel syndrome in North Ameri

Slide 8: IBS: A Significant Underserved Market
IBS: A Significant Underserved Market Diarrhea- Predominant 36% Constipation- Predominant 31% Alternating Diarrhea and Constipation 33% 5-HT 3 Antagonist Lotronex ® (GSK) • Sales: $10 - 12 million* 5-HT 4 Agonist Zelnorm ® (Novartis) • Sales: $370 - 380 million* * Projected 2006 Dextofisopam

Slide 9: Dextofisopam
Dextofisopam PHARMOS

Slide 10: Dextofisopam: Leading Asset in Development for IBS
Dextofisopam: Leading Asset in Development for IBS Dextofisopam Potentially normalizes GI dysmotility Binds to receptors in brain areas modulating GI function Also has broad local anti-inflammatory properties Expectation for good safety profile Good proprietary position Positive Phase 2 data

Slide 11: Dextofisopam: Phase 2a Study Design
Dextofisopam: Phase 2a Study Design Double-blind, US study (33 sites) 141 men and women with diarrhea-predominant or alternating IBS 200 mg BID dextofisopam or placebo for 12 weeks Primary endpoint * : “adequate relief” Weekly… Patient friendly, global measure • FDA accepted measure Secondary endpoi

Slide 12: Dextofisopam Phase 2a Study Results: Summary
Dextofisopam Phase 2a Study Results: Summary Positive effect on primary efficacy endpoint 32% advantage vs. placebo Statistically significant (p = 0.033) Positive effect on key secondary efficacy endpoints Dextofisopam decreased stool frequency and improved (hardened) stool consistency in patients w

Slide 13: Synthetic Cannabinoid Agonists
Synthetic Cannabinoid Agonists PHARMOS

Slide 14: Cannabinoid Receptor Agonists
Cannabinoid Receptor Agonists CB1 R – primarily in brain & nerves Psychoactive effects Pain Satiety (obesity) CB2 R – primarily in immune related cells Immune modulation (multiple sclerosis, rheumatoid arthritis and IBD, atherosclerosis) Pain ( neuropathic pain) Bone formation (osteoporosis) Objecti

Slide 15: CB2 Market Opportunity
CB2 Market Opportunity Pain – large market (> $US 15B annual sales) Significant growth potential. Neuropathic pain – underserved, search for new approach (non- opioid) Multiple Sclerosis – large market potential Need for new effective, safe and orally delivered drugs Other addressable indications Rh

Slide 16: Cannabinor Clinical Trials
Cannabinor Clinical Trials Phase 2a – Proof of principal pain trials * underway (IV formulation) Nociceptive (third molar extraction) 100 patients Neuropathic (capsaicin-induced) 24 subjects Phase 1 trial completed – well tolerated Oral formulation developed * Establish human therapeutic window

Slide 17: Cannabinor – Oral Formulation Program
Cannabinor – Oral Formulation Program Objective: develop product for chronic use Potential indications Neuropathic pain Autoimmune diseases Formulation achieved > 25% bioavailability in pigs Ongoing 28 days tox study in monkeys near completion Clinical Phase 1 trial initiation targeted 1Q2007 Clinic

Slide 18: CB2 Specific Pipeline
CB2 Specific Pipeline PRS-XXX – Objective: Improved Profile Robust efficacy in animal models of pain ( moderate and neuropathic pain) and autoimmune diseases (remitting-relapsing multiple sclerosis and inflammatory bowel disease ) CB1 safety: CB1 side effects (tetrad) were not observed at the highes

Slide 19: CB2 Specific Pipeline
CB2 Specific Pipeline PRS YYY Lead optimization - ongoing Improved drug-like properties CB2 R activation with low CB1 activity Targeted for chronic indications (osteoporosis & atherosclerosis) No safety issues noted in pre-clinical studies

Slide 20: Nano Based Topical NSAID
Nano Based Topical NSAID PHARMOS

Slide 21: Nano Based topical NSAID
Nano Based topical NSAID Osteoarthritis (inflammation of the joints) and other tissue inflammation, very prevalent (30 million in US) and growing with age About 25% are not treated because of side effects (GI & cardio) Pharmos Nano delivery technology aimed to target drug directly to tissue, therefo

Slide 22: Nano Based topical NSAID
Nano Based topical NSAID 3% Diclofenac Nano Emulsion formulation developed Tissue distribution tested in animals demonstrating tissue targeting concept Phase 1 clinical trial to test safety – ongoing Plan to test efficacy in patients (Phase 2) Expect lower regulatory risk with well known NSAID

Slide 23: Company Highlights
Company Highlights PHARMOS

Slide 24: Pharmos Trading/Financial Highlights
Pharmos Trading/Financial Highlights NASDAQ: PARS Market capitalization: $39.1 million Recent price: $2.05 (10/23/06) 52-week high/low: $2.93 - 1.55 Financial (Pre-acquisition): 19.1 million shares outstanding (plus 6.5 million shares to Vela SH) $39.4 million cash/short-term investments (as of 30 J

Slide 25: Pharmos Investment Summary
Pharmos Investment Summary Balanced portfolio Early and later-stage products Dextofisopam – strong Phase 2a IBS data Two cannabinor Phase 2a pain studies [in progress] Progress in building CB2R agonist pipeline Building leadership positions in IBS/CB2

Slide 26: Annual Shareholders Meeting October 2006
Annual Shareholders Meeting October 2006
Source: SEC EDGAR · 8-K filed Oct 26, 2006
